MoonLake Immunotherapeutics CEO Jorge Santos da Silva (L) and CSO Kristian Reich (via website)
July 17, 2023 06:44 AM EDTUpdated 06:55 AM
Deals
Pharma

Moon­Lake’s im­munol­o­gy drug gets help of in­vest­ment bankers for po­ten­tial sale — Reuters re­port

Kyle LaHucik

Senior Reporter

Moon­Lake Im­munother­a­peu­tics is work­ing with an in­vest­ment bank to ex­plore a po­ten­tial sale, per a Fri­day evening re­port in Reuters, cit­ing …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump names Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, Sur­geon Gen­er­al picks

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

Sur­round­ed by AI bio gi­ants, tiny start­up Nabla Bio makes de no­vo an­ti­bod­ies look more like drugs 

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times